FULC Q3 2024 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$25M

Net Income

-$22M

EPS (Diluted)

$-0.35

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$279M

Total Liabilities

$22M

Stockholders' Equity

$257M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$759,000	-100.0%
Gross Profit	$0	-$17M	+100.0%
Operating Income	-$25M	-$27M	+8.4%
Net Income	-$22M	-$24M	+9.7%